These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947 [TBL] [Abstract][Full Text] [Related]
3. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325 [TBL] [Abstract][Full Text] [Related]
4. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905 [TBL] [Abstract][Full Text] [Related]
6. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders]. Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375 [TBL] [Abstract][Full Text] [Related]
7. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Seppi K; Schocke MF; Donnemiller E; Esterhammer R; Kremser C; Scherfler C; Diem A; Jaschke W; Wenning GK; Poewe W Mov Disord; 2004 Dec; 19(12):1438-45. PubMed ID: 15390073 [TBL] [Abstract][Full Text] [Related]
14. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls. Cordes M; Hierholzer J; Schelosky L; Poewe W; Cordes I; Horowski R; Eichstaedt H; Schmidt D; Felix R Adv Neurol; 1993; 60():525-8. PubMed ID: 8420183 [No Abstract] [Full Text] [Related]
15. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354 [TBL] [Abstract][Full Text] [Related]
16. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome. Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182 [TBL] [Abstract][Full Text] [Related]
17. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. Hwang WJ; Yao WJ; Wey SP; Ting G J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637 [TBL] [Abstract][Full Text] [Related]